Jump to Main Content

Programs

ASH Poster Walk

ASH Poster Walk on Current Challenges in Treating Hematologic Malignancies: Live Q&A

Wednesday, December 9, 2020, 7:00 a.m. - 8:00 a.m. Pacific time

The following abstracts will be featured in this session:

1467 - Clinical Characteristics and Outcomes of COVID-19 in HSCT Recipients
Clarisse MARTINS Machado , MD, PhD
Hospital Israelita Albert Einstein
São Paulo,  Brazil

2384 - COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)
Per Ljungman , MD, PhD
Karolinska University Hospital
Stockholm,  SWE

2903 - DNA-Based Methods for Measurable Residual Disease Detection in NPM1-Mutated Acute Myeloid Leukemia; Establishment of Cut-Offs for qPCR, Digital Droplet PCR and Targeted Deep Sequencing
Louise Pettersson
Lund University
Lund,  Sweden

3065 - Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia
Simone Claudiani
Imperial College London
London,  United Kingdom

3329 - Outpatient Transplantation during the COVID19 Pandemic: Stretching the Limits for Continuing Care
Perla R. Colunga Pedraza , MD
Universidad Autonoma de Nuevo Leon, Hospital Universitario 'Dr. José Eleuterio Gonzalez', Servicio de Hematología
Monterrey,  NL, Mexico

Moderator:

Eduardo M Rego , MD,PhD
University of São Paulo
Sao Paulo,  Sp, Brazil

back to top

ASH Poster Walk on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure: Live Q&A

Wednesday, December 9, 2020, 7:00 a.m. - 8:00 a.m. Pacific time

The following abstracts will be featured in this session:

0928 - Disease Progression and Outcomes in Patients with Telomere Biology Disorders
Marena R. Niewisch , MD
National Cancer Institute, National Institutes of Health
Bethesda,  MD

0931 - Impact and Dynamics of TP53 Mutated Clones in Shwachman Diamond Syndrome in a Series of 80 Patients
Jean Donadieu , MD,PhD
Hopital Trousseau
Paris,  Cedex, France

0952 - Germline POT1 Variants Can Predispose to a Variety of Hematologic Neoplasms
Tristan L. Lim , BSc
University of Pennsylvania
Philadelphia,  PA

1091 - Germline Variants Associated with Cancer Predisposition and Bone Marrow Failure Are Common in KMT2A-r Infant Acute Lymphoblastic Leukemia Patients
Sarah Mc Dermott , DO
Children's Mercy
Kansas City,  MO

1997 - Prevalence of Inherited Predisposition Syndromes in Young Patients with Acute Myeloid Leukemia and Aberrant Karyotype
Fabian Beier , MD
University Hospital Aachen
Aachen,  Germany

2749 - Singl­­­e-Cell Transcriptional Landscapes of Human Bone Marrow Reveal Distinct Erythroid Phenotypes Underpinned By Genotype in Diamond-Blackfan Anemia
Deena Iskander , MD
Imperial College London
London,  United Kingdom

Moderator:

David Wu , MD
University of Washington
Diamond Bar,  CA

back to top

ASH Poster Walk on Blood & Bone: From Hematopoiesis to Hemostasis: Live Q&A

December 10, 2020, 7:00 a.m. - 8:00 a.m. Pacific time

The following abstracts will be featured in this session:

0837 - Comprehensive Description of Monoallelic GP1BA Variants Associated with Thrombocytopenia
Rachel C Peck , BSc,MRCP
University of Bristol
Bristol,  ENG, United Kingdom

0910 - RUNX1 Mutation Leads to Megakaryocyte-Primed Hematopoietic Stem Cell Expansion and Familial Platelet Disorder
Chen Wang , MD
University of Cincinnati
Cincinnati,  OH

1761 - Plasma Proteomic Profile Associated with Platelet Dysfunction after Trauma
Alexander E St. John , MD
University of Washington
Seattle,  WA

1832 - Mitochondrial Function Is Impaired in a Subset of Aged Haematopoietic Stem Cells in Response to Infection
Charlotte Hellmich , MBBChir
University of East Anglia
Norwich,  United Kingdom

1834 - Generation of a Low Oxygen Hematopoietic Landscape Identifies Transcriptional and Functional Alterations in Calcium Regulation
Paige Dausinas , BS
IUPUI (IU School of Medicine)
Indianapolis,  IN

2730 - Single Cell Resolution Mapping of Hematopoietic Stem and Progenitor Cell States throughout Human Life
Hojun Li , MD, PhD
Boston Children's Hospital
Boston,  MA

Moderator:

Kellie R. Machlus , PhD
Boston Children's Hospital, Harvard Medical School
Boston,  MA

back to top

ASH Poster Walk on Clinical Trials in Progress: Live Q&A

December 10, 2020, 7:00 a.m. - 8:00 a.m. Pacific time

The following abstracts will be featured in this session:

0752 - Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study
Nichola Cooper , MD
Hammersmith Hospital, Imperial College London
London,  United Kingdom

0860 - First-in-Human Phase 1/2 Clinical Trial of SIG-001, an Innovative Shielded Cell Therapy Platform, for Hemophilia ?
Amy D Shapiro , MD
Indiana Hemophilia & Thrombosis Center
Indianapolis,  IN

1039 - Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Gail J. Roboz , MD
Weill Cornell Medicine, The New York Presbyterian Hospital
New York,  NY

1311 - Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-Based Therapy in Subjects with TP53-Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
Meghan C. Thompson , MD
Memorial Sloan Kettering Cancer Center
New York,  NY

2622 - An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)
Ken W. Wood
Forma Therapeutics, Inc.
Watertown,  MA

2997 - Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis
Andrew Charles Perkins , MBBS,PhD
Monash University
Malvern,  VIC, Australia

Moderator:

Fangxin Hong , PhD
Dana-Farber Cancer Institute
Boston,  MA

back to top

ASH Poster Walk on Exploring Quality Improvement: Live Q&A

December 10, 2020, 7:00 a.m. - 8:00 a.m. Pacific time

The following abstracts will be featured in this session:

1612 - Reducing Cytogenetic Testing in the Era of Next Generation Sequencing (NGS); Are We Choosing Wisely?
Eri Kawata , MD,PhD
London Health Sciences Centre
Kyoto-Shi,  KYO, Japan

1662 - Financial Toxicity Intervention Decreases Mortality in High Risk Hematologic Malignancy Patients
Thomas G. Knight , MD
Levine Cancer Institute, Atrium Health
Charlotte,  NC

2726 - Refining Blood Products Utilization: Every One (unit) Matters. Post-Intervention Study
Caroline Hana , MBBCh
University of Miami/JFK Palm Beach Regional Campus
Boynton Beach,  FL

3408 - Assessing Barriers to Medication Adherence in Pediatric and Adolescent and Young Adult (AYA) Patients on Anticoagulation
Kevin E Todd Jr. , MD
Cincinnati Children's Hospital Medical Center
Cincinnati,  OH

3394 - Optimizing Pain Management for Children with Sickle Cell Disease Vaso-Occlusive Crisis in the Emergency Department
Wilson Andres Vasconez , M.D.
University of Miami/Jackson Memorial Hospital
Miami,  FL

3469 - Reducing Time to Chemotherapy Administration in the Outpatient Setting of a Tertiary Cancer Centre Using a Design Thinking Approach
Wei-Ying Jen , BM BCh, FRCPath
National University Cancer Institute, Singapore
Singapore,  Singapore

Moderator:

Lisa K. Hicks , MD, MSc
St. Michael's Hospital
Toronto,  ON, Canada

back to top

ASH Poster Walk on Hematology and Aging: Live Q&A

December 10, 2020, 7:00 a.m. - 8:00 a.m. Pacific time

The following abstracts will be featured in this session:

1367 - Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis
Jesus G. Berdeja , MD
Sarah Cannon Research Institute and Tennessee Oncology
Nashville,  TN

1645 - Prognosis of Older Adults with Chronic Lymphocytic Leukemia By Comorbidity and Frailty: A SEER-Medicare Cohort Study
Emilie D Duchesneau , BA
University of North Carolina at Chapel Hill, Gillings School of Global Public Health
Chapel Hill,  NC

1946 - Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML)
Jorge E. Cortes , MD
Georgia Cancer Center, Augusta University
Augusta,  GA

1958 - Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation
Jessica K. Altman , MD
Northwestern University
chicago,  IL

2256 - Influence of Aging Processes on the Biology and Outcome of Multiple Myeloma
Eileen M Boyle , MD,MSc
NYU Langone Health
New York,  NY

2628 - Functional Assessment in Younger and Older Adults with Sickle Cell Disease
Charity I Oyedeji , MD
Duke University School of Medicine
Durham,  NC

Moderator:

Ashley Rosko , MD
The Ohio State University
Columbus,  OH

back to top

ASH Poster Walk on Immunotherapies: A Walk Down Immunotherapy Lane: Watch Out for the CARs: Live Q&A

December 10, 2020, 7:00 a.m. - 8:00 a.m. Pacific time

The following abstracts will be featured in this session:

1173 - A Novel Approach for Treatment of T-Cell Malignancies: Targeting T-Cell Receptor Vß Families
Jie Wang , MD,MS
Duke University
Durham,  NC

1442 - High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics
Jordan Gauthier , MD, MSc
University of Washington
Seattle,  WA

2333 - Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells
Viktoria Blumenberg , MD
Department of Medicine III, University Hospital, LMU Munich
Munich,  Germany

2579 - Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria
Peter Hillmen , MBChB, PhD
St James University Hospital
Leeds,  United Kingdom

3255 - Molecular Imaging of Chimeric Antigen Receptor T Cells By ICOS-Immunopet
Federico Simonetta , MD, PhD
Stanford University
Stanford,  CA

3266 - Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH)
Michael B. Jordan , MD
University of Cincinnati College of Medicine
Cincinnati,  OH

Moderator:

Jennifer Holter-Chakrabarty , MD
University of Oklahoma Health Sciences Center
Oklahoma City,  OK

back to top

ASH Poster Walk on Novel Diagnostics and Treatments for Sickle Cell Disease: A New Era: Live Q&A

December 10, 2020, 7:00 a.m. - 8:00 a.m. Pacific time

The following abstracts will be featured in this session:

0786 - Ex-Vivo FT-4202 Treatment Improves Hemoglobin Oxygen Affinity and Membrane Health in Red Blood Cells of Patients with Hemoglobin SS and Hemoglobin SC Disease Irrespective of Prior Hydroxyurea Use
Diamantis G. Konstantinidis , PhD, BSc
Cincinnati Children's Hospital Medical Center
Cincinnati,  OH

0804 - Assessment of Cerebral Blood Flow and Oxygen Extraction in Pediatric Sickle Cell Disease with Non-Invasive Diffuse Optical Spectroscopies
Seung Yup Lee
Georgia Institute of Technology and Emory University
Atlanta,  GA

1708 - Red Cell Rheology Biomarkers to Assess Cure in Gene-Based Therapies
Celeste K. Kanne , BA
Baylor College of Medicine
Houston,  TX

1713 - Real World Clinical Experience with Oxbryta Therapy in Individuals with Sickle Cell Disease
Caterina P. Minniti , MD
Division of Hematology, Montefiore Medical Center.Albert Einstein College of Medicine
Bronx,  NY

1730 - The Grndad Registry: Contemporary Natural History Data and an Analysis of Real-World Patterns of Use and Limitations of Disease Modifying Therapy in Adults with SCD
Alexandra Boye-Doe
University of North Carolina
Chapel Hill,  NC

2633 - Use of Multiple Urinary Biomarkers for Early Detection of Chronic Kidney Disease in Sickle Cell Anemia Patients
Yagahira E. Castro Sesquen
Howard University
Clarksburg,  MD

Moderator:

Melanie E Fields , MD
Washington University in St. Louis
Saint Louis,  MO

back to top

ASH Poster Walk on Healthcare Equity Matters: Live Q&A

December 10, 2020, 2:00 p.m. - 3:00 p.m. Pacific time

The following abstracts will be featured in this session:

1568 - Leveraging Project Echo Telementoring to Improve Sickle Cell Disease Care in the Midwest: Expanding Provider Education during a Pandemic
Lisa M Shook , DHPE (CANCELLED)
Cincinnati Children's Hospital Medical Center
Cincinnati,  OH

1593 - Racial and Ethnic Disparities in Systemic AL Amyloidosis: Examining Differences in Clinical Presentation and Outcomes
Andrew Staron
Boston Medical Center and Boston University School of Medicine
Boston,  MA

2625 - The Impact of Hydroxyurea Use on Cognitive Functioning of Children with Sickle Cell Disease in Ghana
Olubusola Oluwole , MD, MS
University of Washingon
Seattle,  WA

3001 - Low Representation and High Disease Burden in Underrepresented Minority Participants in the Mympn Registry
Alison R. Moliterno , MD
Johns Hopkins University School of Medicine
Baltimore,  MD

3362 - Impact of Race and Geographic Location on Outcomes in Allogeneic Transplant
Audrey M. Sigmund , MD
The Ohio State University
Columbus,  OH

3435 - Exclusion of Patients Living with Chronic Viral Infections and Underrepresentation of Ethnic Minorities in Diffuse Large B-Cell Lymphoma Clinical Trials
Stephanie Boisclair , MD
Memorial Healthcare System
Pembroke Pines,  FL

Moderator:

Rayne H. Rouce , MD
Clinical Care Center-Texas Children's Hospital
Houston,  TX

back to top

ASH Poster Walk on Hemostasis and Thrombosis: Live Q&A

December 10, 2020, 2:00 p.m. - 3:00 p.m. Pacific time

The following abstracts will be featured in this session:

0851 - Liver X Receptor (LXR) Is a Novel and Reversible Regulator of Trauma-Induced Coagulopathy
Kenneth Jones
University of Colorado School of Medicine
Aurora,  CO

1759 - Relapse Prediction Model for Immune-Mediated Thrombotic Thrombocytopenic Purpura
Camila Masias , MD,MPH
Baptist Health
Miami,  FL

1802 - Biomarkers of Hypercoagulability and Endothelial Cell Activation in Patients with Severe COVID-19 Admitted at the Intensive Care Unit. the Roadmap-COVID-19 Prospective Observational Study
Patrick Van Dreden , PhD (CANCELLED)
Stago
Gennevilliers,  France

1801 - Thrombosis Risk in Transgender Adolescents Receiving Gender-Affirming Hormone Therapy
Eric S. Mullins , MD
Cincinnati Children's Hospital Medical Center
Cincinnati,  OH

2655 - Platelet Membrane Procoagulation in Preeclampsia
Adrienne Lee , MD
Cumming School of Medicine University of Calgary
Calgary,  AB, Canada

2685 - Real-World Safety of Emicizumab: The First Interim Analysis of the European Haemophilia Safety Surveillance (EUHASS) Database
Aijing Shang , MD, PhD
F. Hoffmann-La Roche Ltd
Basel,  Switzerland

Moderator:

Lisa B. Kreuziger , MD, MS
Versiti
Menomonee Falls,  WI